Hyderabad, India and Princeton, NJ, USA. July 11, 2018— Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Hydroxychloroquine Sulfate Tablets USP, 200 mg, a therapeutic equivalent generic version of Plaquenil® (hydroxychloroquine sulfate) Tablets, in the U.S. market, approved by the U.S. Food and Drug Administration (USFDA).
The Plaquenil® brand and generic had U.S. sales of approximately $215 million MAT for the most recent twelve months ending in May 2018 according to IMS Health*.
Dr. Reddy’s Hydroxychloroquine Sulfate Tablets are available in 200 mg tablets in the bottle count sizes of 100 and 500.
Plaquenil® is a trademark of Concordia International Corp.
Your email address will not be published. Required fields are marked *
Notify me of follow-up comments by email.
Notify me of new posts by email.
Sign me up for the newsletter!
TVS Motor Company rolls out the 50,000 unit of the BMW 310cc series motorcycle
TCS Recognized as a Leader in Gartner Magic Quadrant for Application Testing Services, WW
Suzlon secures 50.4 MW order from Atria Power
Tata Technologies signs MoU with GIZ to foster industry-academia-government cooperation
NYKAA FEMINA BEAUTY AWARDS ALL SET FOR ITS 5TH EDITION
2014 The Global Indian New Network (TGINN)